Assessing the Optimum Use of Androgen-Deprivation Therapy in High-Risk Prostate Cancer Patients Undergoing External Beam Radiation Therapy

Michelle S. Ludwig, Deborah A. Kuban, Sara S. Strom, Xianglin L. Du, David Lopez, Jose Miguel Yamal

Research output: Contribution to journalArticle

Abstract

The optimum use of androgen deprivation therapy (ADT) in high-risk prostate cancer patients has not been defined in the setting of dose-escalated external beam radiation therapy. A retrospective analysis of 1,290 patients with high-risk prostate cancer from June 1987 through March 2010 treated with external beam radiation therapy was performed. Median follow-up was 7.2 years, and 797 patients received ADT, with 384 patients experiencing a biochemical failure and 145 with distant metastasis. ADT was associated with lower risk of biochemical failure and distant metastasis than no ADT after adjusting for age, prostate-specific antigen (PSA), Gleason score, year of diagnosis, tumor stage, and radiation dose. ADT was associated with a greater reduction in biochemical failure in the low-dose radiation group than in the high-dose group. Patients with >24 months of ADT had a lower risk of PSA failures than those with <24 months. ADT was associated with decreased risk of biochemical failure and distant metastasis in all patients. The effect of ADT on reducing risk of biochemical failure was greater among men with low-dose radiation. There was a benefit in PSA and distant metastasis-free survival with >24 months of ADT in all patients who received ADT.

Original languageEnglish (US)
Pages (from-to)73-81
Number of pages9
JournalAmerican Journal of Men's Health
Volume11
Issue number1
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

deprivation
Androgens
Prostatic Neoplasms
cancer
Radiotherapy
Therapeutics
Prostate-Specific Antigen
Radiation
Neoplasm Metastasis
Neoplasm Grading
Group
Neoplasms

Keywords

  • hormone replacement therapy
  • oncology/cancer
  • outcomes research
  • physiological and endocrine disorders
  • prostate cancer
  • research

ASJC Scopus subject areas

  • Health(social science)
  • Public Health, Environmental and Occupational Health

Cite this

Assessing the Optimum Use of Androgen-Deprivation Therapy in High-Risk Prostate Cancer Patients Undergoing External Beam Radiation Therapy. / Ludwig, Michelle S.; Kuban, Deborah A.; Strom, Sara S.; Du, Xianglin L.; Lopez, David; Yamal, Jose Miguel.

In: American Journal of Men's Health, Vol. 11, No. 1, 01.01.2017, p. 73-81.

Research output: Contribution to journalArticle

Ludwig, Michelle S. ; Kuban, Deborah A. ; Strom, Sara S. ; Du, Xianglin L. ; Lopez, David ; Yamal, Jose Miguel. / Assessing the Optimum Use of Androgen-Deprivation Therapy in High-Risk Prostate Cancer Patients Undergoing External Beam Radiation Therapy. In: American Journal of Men's Health. 2017 ; Vol. 11, No. 1. pp. 73-81.
@article{c54279e4776e402eb8eecc24d6233f37,
title = "Assessing the Optimum Use of Androgen-Deprivation Therapy in High-Risk Prostate Cancer Patients Undergoing External Beam Radiation Therapy",
abstract = "The optimum use of androgen deprivation therapy (ADT) in high-risk prostate cancer patients has not been defined in the setting of dose-escalated external beam radiation therapy. A retrospective analysis of 1,290 patients with high-risk prostate cancer from June 1987 through March 2010 treated with external beam radiation therapy was performed. Median follow-up was 7.2 years, and 797 patients received ADT, with 384 patients experiencing a biochemical failure and 145 with distant metastasis. ADT was associated with lower risk of biochemical failure and distant metastasis than no ADT after adjusting for age, prostate-specific antigen (PSA), Gleason score, year of diagnosis, tumor stage, and radiation dose. ADT was associated with a greater reduction in biochemical failure in the low-dose radiation group than in the high-dose group. Patients with >24 months of ADT had a lower risk of PSA failures than those with <24 months. ADT was associated with decreased risk of biochemical failure and distant metastasis in all patients. The effect of ADT on reducing risk of biochemical failure was greater among men with low-dose radiation. There was a benefit in PSA and distant metastasis-free survival with >24 months of ADT in all patients who received ADT.",
keywords = "hormone replacement therapy, oncology/cancer, outcomes research, physiological and endocrine disorders, prostate cancer, research",
author = "Ludwig, {Michelle S.} and Kuban, {Deborah A.} and Strom, {Sara S.} and Du, {Xianglin L.} and David Lopez and Yamal, {Jose Miguel}",
year = "2017",
month = "1",
day = "1",
doi = "10.1177/1557988315581396",
language = "English (US)",
volume = "11",
pages = "73--81",
journal = "American Journal of Men's Health",
issn = "1557-9883",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Assessing the Optimum Use of Androgen-Deprivation Therapy in High-Risk Prostate Cancer Patients Undergoing External Beam Radiation Therapy

AU - Ludwig, Michelle S.

AU - Kuban, Deborah A.

AU - Strom, Sara S.

AU - Du, Xianglin L.

AU - Lopez, David

AU - Yamal, Jose Miguel

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The optimum use of androgen deprivation therapy (ADT) in high-risk prostate cancer patients has not been defined in the setting of dose-escalated external beam radiation therapy. A retrospective analysis of 1,290 patients with high-risk prostate cancer from June 1987 through March 2010 treated with external beam radiation therapy was performed. Median follow-up was 7.2 years, and 797 patients received ADT, with 384 patients experiencing a biochemical failure and 145 with distant metastasis. ADT was associated with lower risk of biochemical failure and distant metastasis than no ADT after adjusting for age, prostate-specific antigen (PSA), Gleason score, year of diagnosis, tumor stage, and radiation dose. ADT was associated with a greater reduction in biochemical failure in the low-dose radiation group than in the high-dose group. Patients with >24 months of ADT had a lower risk of PSA failures than those with <24 months. ADT was associated with decreased risk of biochemical failure and distant metastasis in all patients. The effect of ADT on reducing risk of biochemical failure was greater among men with low-dose radiation. There was a benefit in PSA and distant metastasis-free survival with >24 months of ADT in all patients who received ADT.

AB - The optimum use of androgen deprivation therapy (ADT) in high-risk prostate cancer patients has not been defined in the setting of dose-escalated external beam radiation therapy. A retrospective analysis of 1,290 patients with high-risk prostate cancer from June 1987 through March 2010 treated with external beam radiation therapy was performed. Median follow-up was 7.2 years, and 797 patients received ADT, with 384 patients experiencing a biochemical failure and 145 with distant metastasis. ADT was associated with lower risk of biochemical failure and distant metastasis than no ADT after adjusting for age, prostate-specific antigen (PSA), Gleason score, year of diagnosis, tumor stage, and radiation dose. ADT was associated with a greater reduction in biochemical failure in the low-dose radiation group than in the high-dose group. Patients with >24 months of ADT had a lower risk of PSA failures than those with <24 months. ADT was associated with decreased risk of biochemical failure and distant metastasis in all patients. The effect of ADT on reducing risk of biochemical failure was greater among men with low-dose radiation. There was a benefit in PSA and distant metastasis-free survival with >24 months of ADT in all patients who received ADT.

KW - hormone replacement therapy

KW - oncology/cancer

KW - outcomes research

KW - physiological and endocrine disorders

KW - prostate cancer

KW - research

UR - http://www.scopus.com/inward/record.url?scp=85006356625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006356625&partnerID=8YFLogxK

U2 - 10.1177/1557988315581396

DO - 10.1177/1557988315581396

M3 - Article

C2 - 25891393

AN - SCOPUS:85006356625

VL - 11

SP - 73

EP - 81

JO - American Journal of Men's Health

JF - American Journal of Men's Health

SN - 1557-9883

IS - 1

ER -